Breaking from tradition. Ignite the path to a cure.

An Interview with Sales Development Executive  Assem Nurlanbekova

[fa icon='calendar'] Apr 22, 2021 2:50:55 PM / by David Deems posted in Insider , Interview

[fa icon="comment"] 0 Comments

 

Read More [fa icon="long-arrow-right"]

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce  Collaboration to Design and Qualify Biomarker-Specific Small  Protein Therapeutics

[fa icon='calendar'] Apr 22, 2021 8:06:39 AM / by David Deems posted in Vyant Bio, Inc , drug discovery , Ordaōs Bio

[fa icon="comment"] 0 Comments

New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials

 

Read More [fa icon="long-arrow-right"]

New research demonstrates the value of patient-specific cancer models in studies of metastasis and drug resistance.

[fa icon='calendar'] Apr 15, 2021 1:26:57 PM / by David Deems posted in Drug resistance , metastasis

[fa icon="comment"] 0 Comments

Cellaria scientists to present latest studies at

AACR 2021

Read More [fa icon="long-arrow-right"]

An Interview with Research Associate Maria Ivanova

[fa icon='calendar'] Mar 24, 2021 4:25:36 PM / by David Deems posted in Insider , Interview

[fa icon="comment"] 0 Comments

 

Read More [fa icon="long-arrow-right"]

Leading innovators collaborate to provide new, patient representative cell culture solutions for smarter in vitro research.

[fa icon='calendar'] Mar 16, 2021 3:44:50 PM / by David Deems posted in Insider , BioLamina

[fa icon="comment"] 0 Comments

Read More [fa icon="long-arrow-right"]

Partnership with Northeastern University to advance new photomedicine therapies for key cancers

[fa icon='calendar'] Jan 4, 2021 12:45:21 PM / by David Deems posted in Pancreatic , Bryan Spring

[fa icon="comment"] 0 Comments

We are pleased to announce a grant collaboration with Dr. Bryan Spring, of Northeastern University. Recently, we sat down with Dr. Spring to understand the value sees with Cellaria cell models when compared to conventional cell lines for pancreatic and ovarian cancer. The ultimate goal of his lab is to reduce cancer recurrence and mortality by establishing new approaches for personalized medicine that address tumor heterogeneity, drug-resistance and molecular mechanisms of treatment.

Read More [fa icon="long-arrow-right"]

Cost, Quality, Quantity: A 4-Point Analysis of Today’s IEQ Options

[fa icon='calendar'] Feb 14, 2018 2:16:57 PM / by Dmitry Shvartsman

[fa icon="comment"] 4 Comments

 

Diabetes research requires the use of insulin-secreting islets of Langerhans[1] that are derived from the pancreas of a human or a mouse. Islets of Langerhans are tiny cell clusters in the pancreas that are responsible for insulin production.  When these cells malfunction, diabetes occurs. Whole islets, or the beta cells derived from islets, are a critical component in diabetes research. For example, they are required when using high-throughput screens (HTS) to identify the next active compound that would lead to an increase in newly-formed beta-cells or to reduce the chance of beta-cell death. Unfortunately, isolation of islets from donor tissues is a technically challenging process, which limits the number of islets available from the individual donor. Also, it is often complicated by the lack of access to donor pancreas tissue.

Read More [fa icon="long-arrow-right"]